Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13), FiscalAI reports. The company had revenue of $5.65 million for the quarter, compared to the consensus estimate of $29.00 million.
Prelude Therapeutics Stock Performance
NASDAQ:PRLD opened at $3.45 on Monday. The company has a 50-day moving average price of $4.00 and a 200-day moving average price of $4.07. Prelude Therapeutics has a 12 month low of $1.29 and a 12 month high of $6.83. The stock has a market cap of $275.32 million, a price-to-earnings ratio of -4.73 and a beta of 1.22.
Analyst Upgrades and Downgrades
A number of research firms have commented on PRLD. JPMorgan Chase & Co. initiated coverage on Prelude Therapeutics in a research report on Thursday, September 17th. They set an “overweight” rating and a $12.00 price target for the company. Wall Street Zen cut Prelude Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Prelude Therapeutics in a research report on Wednesday, July 29th. Citigroup reissued a “market outperform” rating on shares of Prelude Therapeutics in a research note on Wednesday, October 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Prelude Therapeutics in a research note on Tuesday, October 27th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.
Get Our Latest Stock Report on Prelude Therapeutics
About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.
Read More
- Five stocks we like better than Prelude Therapeutics
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
